Paris, January 3, 2022 – The company MEDICAL DEVICES VENTURElaunched in 2021 and listed on the stock exchange since February 2022, aims to invest in Deeptech and MedTech research projects from French research and to accelerate the deployment of start-ups in France and abroad.
MEDICAL DEVICES VENTURE already has 4 majority stakes in strong development:
More than 15 million people each year suffer a cardiovascular accident and the majority of post-stroke patients lose the dexterity of their hand, which causes a significant handicap in the gestures of daily life.
Dextrain is the result of 10 years of research that combines technology (with high precision force sensors), neuro-rehabilitation and artificial intelligence to offer therapeutic digital suites to patients in order to train to recover their hand dexterity.
In one year, Dextrain has won the SOFMER prize, the REEDUCA prize, has been certified Deeptech, won an ANR project, nominated ILAB, and above all convinced major rehabilitation centers to adopt the DEXTRAIN Manipulandum.
The prospects for DEXTRAIN from 2023 onwards are to allow patients to train from home while being in permanent contact with their health professional.
More than a third of the world’s population suffers from skin problems of varying severity(acne, shingles, psoriasis, eczema, herpes, lupus, dermatitis, melanoma, carcinoma) and the environmental impact exacerbates these problems.